CellSource’s interim consolidated results offer a familiar business twist: slightly lower sales, much better profit. For the six months ended April 30, revenue fell 2.5% year on year to ¥1,775 million, but gross profit still increased and selling, general and administrative expenses fell 8.5%. That lifted operating profit to ¥125 million from ¥17 million a year earlier.
| Metric | Interim ended Apr. 30, 2026 | Year-earlier interim | Full-year guide |
|---|---|---|---|
| Revenue | ¥1,775m | ¥1,820m | ¥3,418m |
| Operating profit/loss | ¥125m profit | ¥17m profit | ¥170m loss |
| Ordinary profit/loss | ¥115m profit | ¥18m profit | ¥164m loss |
| Net profit/loss attributable to owners | ¥71m profit | ¥11m profit | ¥136m loss |
The mechanics matter. CellSource said partner medical institutions under contract increased by 81 from the end of the previous fiscal year, to 2,183, and medical-institution support service revenue jumped 72.7% to ¥108,295 thousand. But the core processing business remained softer: combined blood-derived and adipose-derived processing cases slipped to 10,114 from 10,303, and processing-service revenue fell 6.5% to ¥1,116,554 thousand. Revenue drifted lower even as the network kept getting bigger.
Below the operating line, ordinary profit came in at ¥115 million, lower than operating profit. The interim income statement shows non-operating expenses rose to ¥19,461 thousand from ¥4,786 thousand, including ¥11,855 thousand of investment partnership losses.
So why keep a full-year consolidated operating-loss forecast of ¥170 million after a profitable first half? Management left its guidance unchanged and said the current year is meant to deepen a shift toward a problem-solving business model built around cell-processing technology. The company said it will continue strategic investment in research and development, consumer businesses, inbound expansion, support for self-pay care and stronger support measures for medical institutions, and explicitly said that means a temporary operating loss for the full year.
The upshot is clear enough. First-half recovery came from better gross profit and leaner overhead, not from obvious top-line acceleration. Until the softness in processing volumes eases, CellSource is asking investors to read this as proof of cost discipline, not yet proof that the spending year is over.